AbCellera (#ABCL) insiders continued buying shares, extending a strong insider-buying trend over the past several days. Insiders have purchased 147,200 shares worth approximately $1.55M at prices between $10.32 and $11.03, including CFO Andrew Booth and Directors Michael Hayden and John Montalbano. 🔹 Key Highlights 💰 147,200 insider shares purchased for approximately $1.55M. 👤 Buyers include CFO Andrew Booth and Directors Michael Hayden and John Montalbano. 🧬 AbCellera is developing first-in-class antibody medicines. 📈 Insider buying follows positive ABCL635 Phase 2 results. 🤝 Jazz and Vertex collaborations have provided $112M in upfront payments. 💵 AbCellera has $675M+ in liquidity. 💡 Why It Matters Continued insider purchases alongside positive clinical results, strategic partnerships, and a strong liquidity position provide important catalysts for AbCellera as it advances its pipeline. 🚀 Start Your 7-Day FREE ThinkSabio Trial https://www.thinksabio.com/ ThinkSabio — Stocks Simplified